The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib Treatment May Improve Nail Psoriasis

Tofacitinib Treatment May Improve Nail Psoriasis

April 24, 2017 • By Rita Buckley

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study.

You Might Also Like
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis
  • Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

“Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“JAK inhibitors look like they can definitely help,” he tells Reuters Health by email.

The study, online April 7 in the Journal of the American Academy of Dermatology, is a post-hoc analysis of pooled data from two 52-week, multisite, double-blind Phase 3 randomized trials (OPT Pivotal 1 and 2).¹

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

OPT Pivotal 1 and 2 included more than 1,800 patients with moderate to severe plaque psoriasis. Approximately 25% reported a medical history of psoriatic arthritis.

All patients were randomized 2:2:1 to receive 5 or 10 mg tofacitinib or placebo twice daily. At Week 16, those receiving placebo were re-randomized to the two treatment groups. Clinical non-responders were discontinued at Week 28.

The post-hoc analysis, by Dr. Joseph F. Merola from Brigham and Women’s Hospital in Boston and colleagues, included 1,196 patients with nail psoriasis at baseline. They were assessed by Nail Psoriasis Severity Index (NAPSI) score.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

At baseline, patients had an average of seven affected fingernails and mean NAPSI scores ranging from 26.9 to 27.3 across the groups.

Outcomes at week 16 showed that significantly more patients in the tofacitinib groups achieved 50%, 75%, or 100% reductions in NAPSI scores compared with the placebo group.

NAPSI scores fell 50% from baseline in 32.8%, 44.2% and 12% of patients in the 5 mg, 10 mg and placebo groups, respectively; 16.9%, 28.1% and 6.8% saw drops of at least 75%, and 10.3%, 18.2% and 5.1% achieved complete clearance (100% NAPSI-score reduction).

Improvements continued through week 28 and were sustained to Week 52, with complete clearance in 16% of 5 mg patients and 29% of those receiving 10 mg.

The mean number of affected nails decreased to 3.5 and 2.7 in the 5 mg and 10 mg groups,respectively, at Week 52.

Improvements in crossover patients were similar to those who received treated throughout the study. However, NAPSI score declines were lower in patients with psoriatic arthritis.

Dr. Thomas Knackstedt, a dermatologist who specializes in nail disorders at Cleveland Clinic in Cleveland, tells Reuters Health that intralesional steroid injections are an effective way to avoid systemic therapy in patients with disease confined to the nails and minimal cutaneous or joint involvement.

Pages: 1 2 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: nails, plaque psoriasis, Psoriasis, Psoriatic Arthritis, Tofacitinib

You Might Also Like:
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis
  • Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis
  • Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)